- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00523601
Quetiapine Efficacy in Bipolar Depression Study (QUEEN)
October 3, 2008 updated by: AstraZeneca
A 8-Week, Multicenter, Open-Label, Observational Study of the Efficacy of Quetiapine Fumarate (SEROQUEL) Immediate-Release Tablets in Adult Patients With Bipolar Depression
To reassure the clinical study data on Seroquel antidepressant efficacy in patients who are diagnosed as bipolar depression
Study Overview
Status
Completed
Conditions
Study Type
Observational
Enrollment (Anticipated)
2000
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Goyang-si
-
Kyungki-do, Goyang-si, Korea, Republic of
- Research Site
-
-
Kwangyuk-si
-
Daejun, Kwangyuk-si, Korea, Republic of
- Research Site
-
-
Suwon-si
-
Kyungki-do, Suwon-si, Korea, Republic of
- Research Site
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 65 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- The patient and the patient's legal representative (if any) must understand the nature of the study and must have given written consent
- Meet DSM-IV-TR criteria for bipolar depression at the time of baseline
Exclusion Criteria:
- Since this programme intends to describe quetiapine use in routine clinical practice when prescribed as treatment of bipolar depression, there are no programme specific exclusion criteria, other than:
Or, any of the following is regarded as a criterion for exclusion from the programme:
- Serious or unstable, medical illness. Subjects with chronic illness may be included but must be stable and otherwise physically healthy on the basis of a physical examination, medical history
- Known intolerance for or lack of response to quetiapine, as judged by the investigator
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Study Director: Joon-Woo Bahn, AstraZeneca Korea
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
June 1, 2007
Primary Completion (Actual)
October 1, 2007
Study Completion (Actual)
December 1, 2007
Study Registration Dates
First Submitted
August 29, 2007
First Submitted That Met QC Criteria
August 30, 2007
First Posted (Estimate)
August 31, 2007
Study Record Updates
Last Update Posted (Estimate)
October 6, 2008
Last Update Submitted That Met QC Criteria
October 3, 2008
Last Verified
April 1, 2008
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- NIS-NKR-SER-2007/2
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Bipolar Depression
-
University Health Network, TorontoCompletedBipolar Disorder | Bipolar Depression | Bipolar I Depression | Bipolar II DepressionCanada
-
Brigham and Women's HospitalRecruitingDepression | Bipolar Disorder | Bipolar Depression | Major Depressive Episode | Bipolar I Depression | Bipolar II DepressionUnited States
-
Forest LaboratoriesGedeon Richter Ltd.CompletedDepression, BipolarUnited States, Ukraine, Bulgaria, Canada, Colombia, Russian Federation
-
Queen's UniversityPfizer; Providence Health & Services; MDS Pharma ServicesCompletedDepression, BipolarCanada
-
Ewha Womans University Mokdong HospitalWithdrawnDepression, BipolarKorea, Republic of
-
Mclean HospitalTerminatedBipolar Depression Depressed PhaseUnited States
-
AstraZenecaCompletedAcute Bipolar DepressionBrazil, Mexico, Peru, Turkey, Argentina, Chile, Venezuela, Colombia, Guatemala
-
Valerie TaylorUniversity Health Network, TorontoActive, not recruitingBipolar DepressionCanada
-
National University of Ireland, Galway, IrelandStanley Medical Research InstituteCompletedBipolar DepressionIreland
-
Astellas Pharma IncCompleted